DHGWA
SRPT icon

Dixon Hughes Goodman Wealth Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Dixon Hughes Goodman Wealth Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-100
Closed -$9K – 1053
2021
Q4 		$9K Buy
+100
New +$8.55K ﹤0.01% 471

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dixon Hughes Goodman Wealth Advisors's SRPT Position: Q1 2022 in Review

Dixon Hughes Goodman Wealth Advisors sold out of Sarepta Therapeutics (SRPT) in Q1 2022, closing a stake of 100 shares — an estimated $9K sold.

Dixon Hughes Goodman Wealth Advisors first reported a position in SRPT in Q4 2021 and held it in 1 quarter. The position peaked at $9K in Q4 2021. 329 funds tracked by Wall St. Rank hold SRPT as of Q1 2022.

  • Dixon Hughes Goodman Wealth Advisors reported no remaining Sarepta Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Dixon Hughes Goodman Wealth Advisors sold 100 Sarepta Therapeutics shares in Q1 2022, an estimated $9K.
  • Dixon Hughes Goodman Wealth Advisors first reported a position in Sarepta Therapeutics in Q4 2021 and held it in 1 quarter.
  • Dixon Hughes Goodman Wealth Advisors's Sarepta Therapeutics position peaked at $9K in Q4 2021.
  • 329 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2022.

Based on Dixon Hughes Goodman Wealth Advisors's 13F filing for Q1 2022, filed 4 Apr 2022.